Identification of plasma protease derived metabolites of glucagon and their formation under typical laboratory sample handling conditions by James W. Howard (2422279) et al.
Identification of plasma protease derived metabolites of glucagon and their formation under 
typical laboratory sample handling conditions 
James W Howard
1,2†
, Richard G Kay
1
, Tricia Tan
3
, James Minnion
3
 and Colin S Creaser
2
  
1 LGC, Newmarket Road, Fordham, Cambridgeshire,  
CB7 5WW, UK 
2 Centre for Analytical Science, Department of Chemistry, Loughborough University, 
Leicestershire, LE11 3TU, UK 
3 Imperial College, Department of Investigative Medicine, Hammersmith Hospital Campus, 
Du Cane Road, London, W12 0NN, UK 
† Author for correspondence. Tel: +44 (0) 1638 720 500. Fax: +44 (0)1638 724 200 
Email: james.howard@lgcgroup.com 
 
SHORT TITLE Identification and characterisation of glucagon metabolites in plasma 
KEY WORDS glucagon, peptide metabolism, plasma protease, sample handling, aprotinin 
stabilisation. 
RATIONALE: Glucagon modulates glucose production, and is also a biomarker for several 
pathologies. It is known to be unstable in human plasma, and consequently stabilisers are 
often added to samples, although these are not particularly effective. Despite this, there have 
not been any studies to identify in vitro plasma protease derived metabolites; such a study is 
described here. Knowledge of metabolism should allow the development of more effective 
sample stabilisation strategies. 
METHODS: Several novel metabolites resulting from the incubation of glucagon in human 
plasma were identified using high resolution mass spectrometry (MS scan) with positive 
electrospray ionisation. MS/MS scans were acquired for additional confirmation using a 
QTRAP. Separation was performed using reversed phase ultra-high performance liquid 
chromatography. The formation of these metabolites was investigated during a time course 
experiment and under specific stress conditions representative of typical laboratory handling 
conditions.  Clinical samples were also screened for metabolites. 
 
Page 2 of 27 
 
RESULTS:  Glucagon3-29 and [pGlu]
3
glucagon3–29 were the major metabolites detected, both 
of which were also present in clinical samples. We also identified two oxidised forms of 
[pGlu]
3
glucagon3–29 as well as Glucagon19-29, or “miniglucagon”, along with the novel 
metabolites glucagon20-29 and glucagon21-29.   The relative levels of these metabolites varied 
throughout the time course experiment, and under the application of the different sample 
handling conditions. Aprotinin stabilisation of samples had negligible effect on metabolite 
formation.  
CONCLUSIONS: Novel plasma protease metabolites of glucagon have been confirmed, and 
their formation characterized over a time course experiment and under typical laboratory 
handling conditions. These metabolites could be monitored to assess the effectiveness of new 
sample stabilisation strategies, and further investigations into their formation could suggest 
specific enzyme inhibitors to use to increase sample stability.  In addition the potential of the 
metabolites to affect immunochemistry based assays as a result of cross-reactivity could be 
investigated.  
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INTRODUCTION 
Glucagon is a 29 amino acid peptide which is one of multiple hormones that modulates 
glucose production or utilisation to regulate blood glucose levels. It is also a biomarker for 
pathologies such as diabetes, pancreatic cancer or certain neuroendocrine tumours 
[1]
. 
Endogenous glucagon levels in healthy patients are reported between 25-80 pg/mL, which 
may be raised by about 10pg/mL in pancreatic cancer patients, and can reach up to 160 
pg/mL in diabetic patients 
[1]
. 
Glucagon is rapidly metabolised  in humans, with a half-life of approx. 5 minutes in healthy 
subjects, which is raised to approx. 6 minutes in diabetic subjects 
[2]
. The liver and kidney are 
primarily responsible for glucagon metabolism in vivo, although some metabolism also 
occurs in the blood compartment, and a wide range of metabolites have been identified 
[3]
. 
For example, glucagon4-29, glucagon7-29, and glucagon1-13 are formed by hepatocytes in the 
liver 
[4][5]
. Glucagon1-13 and glucagon14-29, and the minor metabolites glucagon1-10, glucagon14-
25 and glucagon23-29,   are similarly  formed by a glucagon receptor linked protease in the 
hepatic plasma membrane 
[3][4]
. The metabolite known as miniglucagon, glucagon19-29, is 
produced after processing of glucagon by liver plasma membranes 
[6]
 and pancreatic cells
[7]
. 
Miniglucagon has a unique biological activity as a modulator of glucagon1-29
[8]
. Furthermore, 
in the kidneys, glucagon is hydrolysed at the proximal tubule’s brush border in the kidneys [9] 
by the serine protease dipeptidyl peptidase IV (DPP IV) 
[10][11]
. DPP IV is also present in the 
liver, pancreatic duct, the endothelial cells of the blood vessels, and as a soluble enzyme in 
blood plasma and therefore similar metabolism is suspected to occur here 
[11]
.  
Many of these metabolites have the potential for biological activity. For example, although 
the C-terminal region of glucagon improves receptor binding, peptides lacking this region, 
such as glucagon1–21 and glucagon1–6, are essentially fully active glucagon derivatives,  but 
with lower potency 
[12]
. In contrast, modifications at the amino-terminus of glucagon, 
including removal of the His residue, have a greater effect on receptor binding affinity and 
biological activity 
[13]
.   
Despite the range of metabolites identified in vivo there have not been any studies to identify 
in vitro plasma protease derived metabolites. However in serum diluted to 20% with Tris 
buffer (0.1 mM, pH 7.6) , it has been reported that DPP IV hydrolyses glucagon1-29 to 
glucagon3–29, which then undergoes immediate conversion to exclusively form pyroglutamyl 
glucagon3–29 ([pGlu]
3
glucagon3–29) 
[10]
. This may partially account for the instability glucagon 
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shows in human plasma. For samples intended for glucagon quantitation, inhibitors, such as 
the serine proteinase inhibitor aprotinin or the proprietary P800 cocktail inhibitors are often 
added to samples to stabilise them. However, the effectiveness of these is controversial, for 
example it has been shown that glucagon levels are unaffected by the presence of aprotinin 
[14]
. Similarly, whilst some studies demonstrated that P800 cocktails inhibitors increase 
glucagon half-life to at least 16 hours 
[15]
 and 48 hours 
[16]
, another demonstrated they had an 
insignificant effect 
[17]
.   
In view of the wide range of metabolites formed in vivo it seemed likely that plasma 
metabolites would also be formed in vitro. The formation of additional metabolites could also 
help to explain the poor precision and accuracy 
[18][19][20]
 experienced by many immunoassay 
based glucagon quantitation kits due to cross reactivity with them. Cross reactivity with 
peptides related to glucagon (oxynotomodulin and/or glicentin) has been reported in 4/7 
immunoassay kits 
[19]
 and in 1/3 sandwich ELISA kits 
[20]
 recently evaluated. It could also 
help to explain the 7-fold difference in endogenous glucagon concentrations reported by 
immunoassays directed against the middle or C-terminal regions of glucagon 
[21]
. LC/MS 
assays have the potential to circumvent such issues; however until recently 
[22][23]
 such assays 
were not sensitive enough to detect endogenous glucagon 
[24][25][26]
. 
In this article we report the identification of novel metabolites formed in vitro by human 
plasma protease metabolism of glucagon, and characterise their formation. We also assess 
metabolite formation under typical laboratory sample handling conditions, and investigate the 
effectiveness of aprotinin stabilisation. 
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EXPERIMENTAL 
Materials 
Certified human glucagon (HSQGTFTSDYSKYLDSRRAQDFVQWLMNT) was obtained 
from EDQM (Strasbourg, France). Water was produced by a Triple Red water purifier 
(Buckinghamshire, U.K.). Human plasma was obtained from CTLS (London, UK).  
Aprotinin from BioUltra was obtained from Sigma-Aldrich (Dorset, UK). Plasma was 
stabilised using aprotinin at 100 KIU/mL as appropriate. All chemicals and solvents were 
HPLC or analytical reagent grade and purchased from commercial vendors.  
Preparation of Glucagon Stock Solutions 
1 mg/mL glucagon stock solutions were prepared in borosilicate vials using MeOH: H2O: 
formic acid (FA): bovine serum albumin (BSA), (20:80:0.1:0.1, v/v/v/w) as a solvent and 
stored at -20C when not in use. 
Preparation of Metabolite Samples 
Glucagon samples were prepared by diluting the stock solution 100 fold with human plasma 
to create samples at 10 µg/mL. Plasma was unstabilised unless stated otherwise. Samples 
were extracted either immediately, or after storage at set time points under specific 
conditions. Samples were extracted on wet ice (ca +4 C) using a protein precipitation 
methodology. Briefly samples (100 µL) were placed into a 1mL 96 well plate polypropylene 
plate, precipitated using 500 µL of acetonitrile (ACN): H2O (75:25), vortex mixed, and then 
centrifuged for 10 minutes at 2300g. The supernatant was transferred to a 1mL 96 well lo-
bind plate and evaporated to dryness under nitrogen at 40 C. Samples were reconstituted in 
700 µL 0.2% formic acid (aq) to form “concentrated extracts”, vortex mixed and centrifuged 
again, before being analysed by LC/MS as described below.  To avoid the most abundant 
metabolites leading to detector saturation the extracts were also diluted to form “diluted 
extracts” and re-analysed by LC/MS.  For this dilution, 100 µL of the “concentrated extracts” 
was added to 250 µL 0.2% formic acid (aq) and 350 µL MeOH: H2O: FA: BSA, 
(20:80:0.1:0.1, v/v/v/w) in a 1 mL 96 well lo-bind plate, before being vortex mixed and 
centrifuged. 
Initial Metabolite ID Experiments 
The LC/MS system consisted of a Waters Acquity UPLC system (Waters Corporation, 
Milford, Massachusetts, USA) coupled to an AB SCIEX 5500 QTRAP (Applied Biosystems 
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/ MDS SCIEX, Ontario, Canada) with an electrospray ion source. Data acquisition and 
processing were performed using Analyst 1.5.2 (Applied Biosystems/ MDS SCIEX).  
The mass spectrometer was operated in positive ion mode with an electrospray voltage of 
5500 V, an entrance potential of 10 V, and a declustering potential of 70 V.  The source 
temperature was 600 C, the nitrogen curtain gas 40 Psi, and the nitrogen desolvation gases, 
GS1 and GS2, were set at 60 psi and 40 psi respectively.  Full scan spectra were acquired 
using quadruple mode over the range m/z 450 - 1250 with a scan rate of 2000 (m/z)/sec and 
with unit resolution. 
Glucagon was separated on a Waters UPLC BEH C18 1.7 µm (2.1 x 100 mm) column 
maintained at 60 C. The mobile phase consisted of (A) 0.2% FA (ACN) and (B) 0.2% FA 
(aq). The gradient for separation was 10 – 50% A over 7.9 minutes. The column was then 
cleaned with 95% A for approx. 1 minute then 10% A for approx. 4 minutes. The flow rate 
was 0.8 mL/min and the total run time 13 minutes. 10 µL of the “concentrated extracts” from 
plasma samples incubated at 0 hours and 25 hours at room temperature was injected, and the 
total ion chromatograms were compared to putatively identify metabolites.  
An Enhanced resolution (ER) spectrum of the 25 hour sample was similarly acquired using 
linear ion trap mode with a scan rate of 250 (m/z)/sec over the mass range m/z 800 – 830. An 
Enhanced Product Ion (EPI) spectrum of the m/z 815.6 ion from the 25 hour sample was also 
similarly acquired using Q1 at unit resolution to select the precursor, and using the linear ion 
trap at a scan rate of 10,000 (m/z)/sec over the range m/z 100- 1000  to monitor the product 
ions.  
Metabolite ID Confirmation 
The LC/MS system consisted of a Dionex LC system (Thermo Scientific, Waltham 
California, USA) coupled to Q Exactive Orbitrap system (Thermo Scientific) with an 
electrospray ion source operating in positive ion mode. A scan range of m/z 233.4 – 3500 was 
selected with a resolution of 140,000 (FWHM) with centroid data acquisition.  Data 
acquisition and processing were performed using Xcalibur V2.2 (Thermo Scientific). The LC 
conditions were based on those described above. A “concentrated extract” of a sample 
incubated for 75 hours at room temperature was injected (10 µL), and peaks corresponding to 
those observed during the analysis with the AB SCIEX 5500 Q TRAP were observed.  
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Time Course Studies  
Samples were prepared and extracted as described above after 0, 0.5, 1.5, 3, 25, 49, and 75 
hours storage at room temperature. Quantitation was performed using the LC/MS system 
used for the initial metabolite ID experiments, but using selected reaction monitoring (SRM) 
transitions; m/z 697.5693.8, m/z 815.6811.0, m/z676.9478.2, m/z 641.3632.3, m/z 
577.3478.2, and  m/z 811.1807.0. These transitions corresponded to the most sensitive 
SRM transitions for Glucagon1-29, Glucagon3-29, Glucagon19-29, Glucagon20-29, Glucagon21-29, 
and [pGlu]
3
glucagon3–29 respectively. The nitrogen collision gas was set to medium and both 
transitions used collision energies of 15-20 eV and collision exit well potentials of 13 eV. 
Excel 2010 (Microsoft, Washington, USA)  was used to fit glucagon1-29 degradation to an 
exponential equation. 
Metabolite Formation in Solution 
Glucagon stock solutions (1 mg/mL) were stored at -20 C for 310 days or under ambient 
conditions for 50 hours, and diluted to 204 ng/mL with MeOH: H2O: FA: BSA, 
(20:80:0.1:0.1, v/v/v/w) prior to analysis with the SRM method described above.  
Metabolite Formation in Unstablised and Aprotinin Stabilised (100 KIU/mL) Human 
Plasma  
Aprotinin stabilised (100 KIU/mL) or unstabilised human plasma glucagon samples were 
prepared to a concentration of 10 µg/mL as described above. Samples were extracted as 
described above after; storage for  0 hour, at room temperature or 4 C for 6 hours 20 minutes 
and 26 hours , after 4 freeze-thaw  cycles (-20 C to 4 C) and (-80C to +4 C), and after 1 
month and 5 months storage at -20 C or -80 C. In all cases n=6 replicates were extracted. 
“Concentrated extracts” and “diluted extracts” were analysed using the SRM method 
described above.  
Metabolites formed in Physiological Study Samples 
Physiological Study Samples were obtained from Imperial College London.  The samples 
originated from 5 different individuals who were each infused with a glucagon solution at 
either 16 or 20 pmol/kg/min for 12 hours subcutaneously. Blood samples at various time 
points were collected in 5mL lithium heparin collection tubes containing 1000 KIU of 
Aprotinin, spun down in a cold centrifuge within 5 to 10 mins of collection, and then stored 
at -20 C. The samples (n=87) were analysed using the 2D extraction procedure described 
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previously [23], and the SRM method described above. The study was approved by the West 
London Research Ethics Committee (reference no.11/LO/1782). All volunteers gave written 
informed consent, and the study was planned and performed in accordance with the 
Declaration of Helsinki 
[27]
. 
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RESULTS AND DISCUSSION 
Initial Metabolite ID Experiments (LRMS) 
Initial metabolite ID experiments were performed using low resolution mass spectrometry 
(LRMS) in full scan mode (m/z 450-1250). Overlaying spectra from spiked glucagon human 
samples stored at room temperature for 0 hours and 25 hours revealed several potential 
metabolite peaks (Figure 1). 
 
 
Figure 1 Overlay of MS full scan total ion chromatograms (TICs) from spiked 
glucagon samples (10 µg/mL) stored at room temperature for 0 hours 
(red) and 25 hours (blue). 
 
The mass spectrum from peak 1 contained ions corresponding to the parent glucagon1-29 
molecule, whilst peak 6 contained ions corresponding to the 3+ and 4+ charge state of the 
known 20% serum (buffer) metabolite [pGlu]
3
glucagon3–29.  The peak at approximately 4.7 
minutes was found to have several ions with m/z values consistent with glucagon19-29, 
glucagon20-29, and glucagon21-29. It was determined that these three metabolites eluted at 
slightly different retention times (Peaks 3, 4, and 5 respectively).  
  
2a 
1 (Glucagon) 
2b 
3, 4, 5 
4 2c 
6 
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Peaks 2a, 2b and 2c, contained similar ions that corresponded approximately to those 
expected by the 3+ and 4+ charge state of glucagon3-29 (Table 1). Glucagon3-29 was not 
reported in the related matrix 20% serum (buffer), as it was suggested that the cyclisation to 
form [pGlu]
3
glucagon3–29, occurred immediately (Figure 2) 
[10]
.Such cyclisation may be 
performed by a transglutaminase serum enzyme such as glutaminyl cyclase. 
[28]
 It is possible 
that such enzymes are less active in plasma than in buffered serum, thereby allowing 
significant levels of glucagon3-29 to remain. The enzymatic nature of the cyclisation may also 
explain why it does not occur for position 2 modified glucagon analogs 
[13]
, as these may 
introduce steric hindrance. 
 
 
 
 
 
 
 
Figure 2  Metabolism of glucagon by dipeptidyl peptidase IV (DPP IV) in solution 
and in 20% human serum (buffer) reported in the literature 
[10]
. 
 
Previously double peaks were observed for glucagon3-29  in solution, which were attributed to  
cis/trans isoforms of the truncated molecules
[10]
. To investigate whether this could be the 
origin of the multiple peaks observed in human plasma, a higher resolution scan was acquired 
using the ion trap functionality of the mass spectrometer (Figure 3). The first isotopic peak 
detected in 2a was m/z 814.8, whilst in 2c it was m/z 815.1. Taking into account the 4+ 
charge state, this corresponds to approximately one mass unit difference, demonstrating that 
the species are not isoforms. The spectrum for 2b was not of a high enough quality for a 
similar comparison to be made.  Often when a peptide is one mass unit higher than expected 
it is indicative that a deamidation has occurred, however this is not thought to be the case 
here as the deamidated product usually elutes earlier than the native form.  
Glucagon
3-29
 pyroglutamyl 
glucagon3–29 
Glucagon
1-29
 
Glucagon
5-29
 
DPP IV 
(Pathway In solution) 
DPP IV   
(pathway in 20% serum (buffer) 
 & solution) 
Unknown transglutaminase enzyme 
(Pathway In 20% serum (buffer)) 
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The MS/MS spectra suggested that 2a and 2b were similar, but that 2c was markedly different 
showing less overall fragmentation as evidenced by the high intensity of the precursor ion 
(Figure 3). Assuming neutral loses (i.e. no loss of charge), metabolites 2a and 2b show losses 
of approximately 17.6 Da, which may correspond to water. Whereas 2c shows losses of 
approximately 17.2 Da and 17.6 Da, which may correspond ammonia and water respectively. 
Despite this putative structural information, it was not possible to confirm the identity of 
metabolites  2a,2b or 2c at the resolution offered by LRMS. 
 
Figure 3  Left- Higher resolution MS data of a spiked glucagon sample (10 µg/mL) 
stored at room temperature for 25 hours.  
Right- Product ion (MS/MS) data of m/z 815.6 from a spiked glucagon 
sample (10 µg/mL) stored at room temperature for 25 hours.  
 
In summary, LRMS allowed 8 metabolites to be detected and putatively identified (Table 1)  
However due to the low mass accuracy of the technique it was not possible to distinguish 
between the metabolites corresponding to peaks 2a, 2b, and 2c;  all of which were assigned 
the putative identity of glucagon3-29.Therefore further studies were performed using high 
resolution mass spectrometry (HRMS).  
  
2a 
2b 
2c 
2a 
2b 
2c 
Page 12 of 27 
 
Metabolite ID Confirmation (HRMS) 
High resolution mass spectrometry (HRMS) at a resolving power (FWHM) of 140,000 at m/z 
200, led to a resolution of m/z 0.001 
[29]
, as exemplified in Figure 4. This allows <5 ppm mass 
accuracies to be achieved, rather than the several hundred ppm offered by the LRMS, and 
therefore provided sufficient mass accuracy for the unequivocally identification of novel 
species.  In addition, the HRMS instrument has a higher m/z limit than the LRMS 
spectrometer (m/z 4000, cf 1250) allowing a greater number of charge states to be observed 
for additional confirmation.  
 
Figure 4  HRMS data observed for peaks 2a (top), 2b (middle), and 2c (bottom).  
Much higher resolution is obtained than with the QTRAP operating in 
linear ion trap mode (Figure 3).  
 
2a) 
2b) 
2c) 
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A spiked glucagon sample (10 µg/mL) stored at room temperature for 75 hours was analysed 
using HRMS. Peaks corresponding to those observed during the analysis with the Q TRAP 
were identified and metabolite IDs determined (Table 2). Peak 4 was confirmed as 
[pGlu]
3
glucagon3–29  (2.0 ppm) and Peak 2c was assigned as glucagon3-29 (2.0 ppm). 
Peaks 2a and 2b were assigned as oxidised [pGlu]
3
glucagon3–29 (2.0 ppm).  The 
assignments of peaks 2a, 2b and 2c are corroborated by the MS/MS data acquired by LRMS 
(Figure 3), as only glucagon3-29 can produce a product ion corresponding to the loss of the 
terminal ammonia, as this has already occurred from the oxidised [pGlu]
3
glucagon3–29 forms 
due to pyroglutamisation. 
The oxidised forms of [pGlu]
3
glucagon3–29 are likely to be two diastereomeric methionine 
sulfoxide (MetO) peptides formed by methionine oxidation (Figure 5). Met(O)  peptides are 
the only stable peptide oxidation products, unlike for example reversible cysteine sulfenic 
acid formation, which only act as transient intermediates 
[30]
. The S and R forms of Met(O) 
peptides can be however be reduced back to Met by methionine sulfloxide reductases (Msrs) 
A (msrA) and B (msrB) respectively, in roles associated with protection of peptides against 
oxidative stress and regulation of the aging process 
[31]
.  
It is not possible to assign each peak to a particular methionine sulfoxide diastereoisomer, as 
no robust method exists
[32]
. The partially resolved nature of peaks 2a and 2b corroborates 
their assignment, as peptides containing diastereomers of Met(O) are known to be 
challenging to separate under reversed-phase liquid chromatography conditions 
[32]
.  
 
Figure 5  Diastereomeric structure of methionine sulfoxide, Met-S-(O) and Met-R-
(O). Here, Met-S-(O) denotes the diastereomer with the (S) configuration 
at the alpha carbon and (S) configuration at the sulfur, whereas Met-R-
(O) indicates the (S) configuration at the alpha carbon and (R) 
configuration at the sulphur 
[32]
. 
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Peaks 3, 4, and 5 were confirmed as glucagon21-29, glucagon20-29,  and glucagon19-29
 
  to within 
3.8 ppm. These peaks showed lower mass accuracies than the other metabolites, which is 
likely to be due to their lower abundances limiting mass spectrometer signal.    
Glucagon19-29, or miniglucagon, has previously only been identified in liver plasma 
membranes 
[6]
 and pancreatic cells
[7]
, whereas glucagon20-29, and glucagon21-29
 
 have not been 
previously reported. Miniglucagon, has its own unique biological activity, which is opposite 
to that of gluagon1-29, and thus acts as a modulator
[8]
. Further studies are needed to determine 
whether glucagon20-29 and glucagon21-29
 
might have similar roles.  It has been suggested that 
glucagon19-29, is  formed by insulin degrading enzyme (IDE), a neutral thiol-
metalloendopeptidase, also called insulysin, in liver cells by the cleavage of Arg
18
-Ala
19 
bonds 
[33]
. However other studies have suggested that IDE cleaves at Arg
17
-Arg
18
 bonds with 
the formation of glucagon18-29, which may then be converted into glucagon19-29 by an 
unidentified aminopeptidase like enzyme 
[34]
. It is possible that such residual hepatocyte 
enzymes are present in plasma leading to the formation of glucagon19-29, and perhaps lead to 
the formation of glucagon20-29 and glucagon21-29 by similar unidentified aminopeptidase like 
enzymes. 
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 Time Course Studies  
Incubation of glucagon in human plasma at room temperature for various times (0, 0.5, 1.5, 3, 
25, 49, and 75 hours) showed the rate of glucagon degradation and metabolite formation 
(Figure 6). Due to the differences in abundances of the species it was not possible to 
accurately analyse all species in the same run, as an extract concentration that ensured 
sufficient signal for lower abundant species led to saturation for higher abundant species. 
Therefore the extracts were analysed twice; once “concentrated” and once “diluted”. 
 
 
 
Figure 6  Degradation of glucagon, and formation of metabolites, by human plasma 
incubated at room temperature, monitored by SRM mass spectrometry. 
Top (injection of the “diluted extract”); Middle+ Bottom (injection of the 
“concentrated extract”). 
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LC/MS peak areas were used to create the metabolite profiles. Whilst these are not expected 
to be absolutely related to molar metabolite abundances, due to differences in ionisation 
ability of the metabolites, there is expected to be a loose correlation.  
Glucagon1-29 decayed with an observed half-life (t1/2) of 12.5 hours. This is considerably less 
than the calculated (t1/2) of 19.2 hours from the fitted exponential curve, demonstrating the 
decay is only approximately exponential. Glucagon3-29 was the metabolite that gave the most 
intense signal between 0.5 – 3 hours, whilst the previously reported 20% serum (buffer) 
metabolite [pGlu]
3
glucagon3–29
 
was the most intense at later time points. This was expected 
due to the reported irreversible cyclisation of the N terminal of glucagon3-29
 
to form 
pyroglutamyl 
[10]
. 
[pGlu]
3
glucagon3–29
 
 signal peaks at approximately 32 hours before decreasing, indicating 
that it is itself metabolised. Oxidised metabolites are first detected at 1.5 hours, compared to 
0.5 hours for the [pGlu]
3
glucagon3–29
 
 metabolite. The oxidised a and b forms show similar 
profiles and peak at approximately 30 hours, a similar time to the parent metabolite. However 
the b forms starts to increases again at 75 hours, whereas the a form continues to decrease. In 
addition, the a form gives a lower signal than the b form. Whilst the oxidation of the free 
amino acid Met by hydrogen peroxide in aqueous solution yields a racemic diastereomeric 
mixture of methionine sulfoxides 
[35]
, this will not necessary be the case when Met is part of a 
larger peptide and undergoing enzymatic oxidation . Therefore it is not unexpected that 
different signals were measured, or that the profiles for the two oxidised metabolites are 
slightly different. 
The novel metabolite Glucagon21-29 initially had the fastest rate of formation of the minor 
metabolites, however this slowed with time and abundance peaked at approximately 49 hours 
before decreasing. In contrast Glucagon19-29, or miniglucagon, and the novel metabolite 
Glucagon20-29 showed relatively linear rates of formation, and abundance of these metabolites 
does not appear to have peaked. It might be expected that these small peptides are formed 
sequentially, however the kinetics plots do not corroborate a simple model for this, as the 
larger peptides (glucagon19-29
 
 and glucagon20-29)
 
 continue to increase in abundance with 
time, whereas the smallest peptide (glucagon21-29) plateaus and starts to decrease. Longer time 
course studies may allow the metabolism of these small peptides to be better understood, but 
for a more complete understanding synthetic peptides of these metabolites could be acquired 
and incubated. 
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The degradation of glucagon and the formation of metabolites in human plasma 
samples subjected to typical laboratory handling conditions  
No metabolites were observed when glucagon solutions at 1 mg/mL were stored at -20 C for 
310 days or under ambient conditions for 50 hours. Hence confirming that the metabolites do 
not arise from impurities in the reference material nor are they formed in solution under 
normal experimental conditions. 
In order to access the formation of metabolites under typical laboratory handling conditions, 
samples were prepared in unstabilised human plasma at 10 µg/mL. Due to the controversy 
over the ability of Aprotinin to prevent glucagon degradation 
[14]
. Further samples were also 
prepared in plasma containing 100 KIU/ML of Aprotinin to investigate this. Figure 7 and 
Figure 8 shows metabolite formation under the applied conditions.  
 
Figure 7  Degradation of glucagon1-29, and formation of metabolites, in human 
plasma samples placed under various conditions monitored by SRM mass 
spectrometry. This figure and Figure 8 are created from data acquired by 
injecting the “concentrated extract” and consequently underestimate 
glucagon1-29 degradation due to mass spectrometer detector saturation. A 
“diluted extract” was injected to assess glucagon1-29 degradation, and 
provides the glucagon degradation values quoted in the text. 
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Figure 8  Degradation of glucagon1-29 and formation of metabolites, in human 
plasma samples placed following storage in a freezer at -20 C or -80 C 
for 5 months, and monitored by SRM mass spectrometry.  
 
Glucagon1-29 degradation was observed across all of the stress conditions investigated, except 
for the aprotinin stabilised samples frozen for 1 month (Table 3). Apart from these samples 
the use of aprotinin had a negligible effect, for example after 6 hours 20 minutes at room 
temperature, glucagon1-29 in unstabilised samples had degraded to 58.3% of their 0 hr level, 
whereas in aprotinin stabilised samples it had degraded to 60.7%. Whilst aprotinin’s lack of 
stabilisation ability has been reported previously 
[14]
 this study used C-terminal directed 
antibodies and antibodies directed against the 6-15 region of glucagon, and therefore was not 
able to assess the impact of aprotinin in preventing N-terminal degradations. In contrast, our 
LC/MS assay assessed degradation across the entire molecule, thereby assessing whether 
aprotinin has a stabilising effect across the whole molecule. It appears that aprotinin only has 
a minimal stabilising effect, which requires slow metabolism kinetics, such as those 
experienced in frozen samples, to be observed.  
As expected lowering the temperature reduced glucagon degradation. For example after 6 
hours 20 minutes at 4C glucagon had degraded to approximately 86% of 0 hour levels; this 
corroborates our previous observations 
[23]
. Conversely increasing the storage time increased 
degradation. For example, after 26 hours 20 minutes at room temperature glucagon had 
degraded to approximately 11% of 0 hr levels. Subjecting samples to 4 freeze-thaw cycles 
(cycling at -80 C / +4 C, or -20 C / +4 C) led to degradation to approximately 84% of 0 
hour levels, with no significant difference between the different storage temperatures. The 
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total amount of time these samples spent at 4C before extraction was 4 hours 10 minutes, 
even though the degradation is similar to non-freeze-thaw samples left at 6 hour 20 minutes 
4C, suggesting the process of freeze-thawing may lead to additional degradation, which is 
again consistent to that observed previously 
[23]
.  
Glucagon3-29 was the most intense metabolite for samples with relatively low levels of 
glucagon degradation, for example those stored at 6hr 20 mins at 4C, freeze thaw samples, 
and frozen samples. This is in agreement with the time course studies above, which showed 
that Glucagon3-29 levels peak, before further metabolism into [pGlu]
3
glucagon3–29. Despite 
being the most intense metabolite the response was fairly low, for example the 6 hours 20 
minutes at 4C samples gave glucagon3-29 responses of approximately 6% their 0 hour 
glucagon1-29 response. However as explained above the responses do not necessary correlate 
with abundances. The formation of such metabolites would lead to inaccurate quantitation if 
C-terminal directed antibodies were used as the basis of an immunoassay quantitation 
method. In fact, all of the metabolites detected have intact C-terminals so all have the 
potential to cross react with such antibodies.  
Samples stored at -80 C showed less glucagon degradation than those -20 C (Table 3) and 
correspondingly metabolite formation was greater at -20 C than -80 C (Figure 8).  
Interestingly oxidised [pGlu]
3
glucagon3–29  was not observed in samples stored at  -80 C, this 
is despite similar levels of [pGlu]
3
glucagon3–29   being present as in -20 C samples. 
 
Metabolites formed in Physiological Study Samples 
Plasma samples (n= 87) from a physiological Study involving the infusion of glucagon were 
extracted using the sensitive 2D method before analysis with SRM. The samples were 
analysed in two sets with the second set was assayed two months after the first. The extracts 
were also analysed using our glucagon quantitation method 
[23]
 and found to contain a 
maximum of 1.3 ng/mL of glucagon, which is 7,692 fold less than the 10 µg/mL samples 
used for the experiments described above. Therefore due to the low levels, we were not 
anticipating being able to observe all of the metabolites. 
 
Despite the low glucagon1-29 concentrations, glucagon3-29 was detected in the majority of 
samples (78%) and was found to approximately track glucagon1-29 levels (Figure 9 a-d). The 
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first set of samples (n=25) gave mean glucagon3-29 levels of 14.3% (CV=33.4) of glucagon1-29 
levels (Figure 9 a,c,d), whilst the second set (n=62) gave mean glucagon3-29 levels of 9.0% 
(CV= 28.1) (Figure 9 b). [pGlu]
3
glucagon3–29 was detected in 10% (n=9) of the samples, all 
of which were from one subject (volunteer 3) and was analysed as part of the first set of 
samples (Figure 9 c-d). The levels were approximately half of glucagon3-29 levels (mean= 
48.3%, CV=12.9%, 2 outliers excluded). The low levels of glucagon likely prevented this 
metabolite, and others, from being detected in other samples. If glucagon is measured by 
immunoassays techniques that do not require an intact N terminus 
[14]
  then these metabolites 
could cause glucagon levels to be overestimated.  
Freshly prepared QC samples were extracted alongside the clinical samples, and did not 
contain detectable metabolites, thereby demonstrating that those observed were not an 
artefact of the extraction procedure. However clinical samples were stored at -20 C before 
analysis, and as described previously metabolites were formed in spiked samples stored under 
these conditions. Specifically, after 5 months storage glucagon3-29 was detected at 3.3% of 
glucagon1-29 levels (CV=8.7%) whilst [pGlu]
3
glucagon3–29 
 
was detected at 23.1% of 
glucagon3-29 levels (CV=11.9); these values were lower at 2.8% (CV=3.6%) and 11.8% 
(CV=15.1%) after 1 month storage. However, as clinical samples were analysed within 5 
months and their mean detected glucagon3-29 levels are up to 4.3 fold greater, and mean 
[pGlu]
3
glucagon3–29
  
levels are 2.1 fold greater, than those observed in the spiked samples this 
suggests that at least some metabolism occurs in vivo. 
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Figure 9  Glucagon metabolites detected in clinical samples.  
a) Glucagon1-29 and glucagon3-29.  
b) Glucagon1-29, glucagon3-29 and Glucagon3-29 scaled by a factor of 10 to 
emphasise the    __relationship between the metabolite and parent levels.  
c) Glucagon1-29, Glucagon3-29, and [pGlu]
3
glucagon3–29.  
d) Glucagon3-29, and [pGlu]
3
glucagon3–29only.
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CONCLUSION 
Metabolites formed from the incubation of glucagon1–29 in human plasma have been 
identified using high resolution mass spectrometry. The presence of the previously reported 
20% serum (buffer) metabolite pyroglutamyl [pGlu]
3
glucagon3–29 was confirmed, however 
we also detected significant amounts of  glucagon3–29
 
which has not been reported in buffered 
serum. In fact, at low levels of glucagon metabolism this was the major metabolite. 
Glucagon19-29, or miniglucagon, was also identified in plasma, which has previously only 
been observed in liver plasma membranes 
[6]
 or pancreatic cells
[7]
. We also identified the 
novel metabolites glucagon20-29 and glucagon21-29. Further studies are needed to determine 
whether these, like minglucagon, have an important function in vivo. Additionally we 
identified two oxidised forms of [pGlu]
3
glucagon3–29. All of the metabolites identified  
contain an intact C-terminal and have the potential to cross react with antibodies in 
glucagon1-29 immunoassays that are directed again this portion of the molecule 
[14]
. This could 
lead to lead to inaccurate glucagon1-29 quantitation and consequently clinical decisions could 
be made on the basis of inaccurate data. 
Metabolite formation was investigated under various stress conditions, representative of 
typical laboratory sample handling conditions. Aprotinin stabilisation was found to have 
negligible effect demonstrating more effective stabilisation approaches should be developed.   
Despite the low levels of glucagon present in the clinical samples the glucagon3-29 metabolite 
was detected in the majority of them, and was the major metabolite, whilst  
[pGlu]
3
glucagon3–29 was detected in just one subject. However, at least some of the 
metabolites observed are likely to be formed as a result of in vitro plasma protease 
metabolism that occurs during sample storage rather than being formed in vivo, again 
emphasising the need for alternative stabilisation approaches. Once these are developed, the 
in vivo formation of the novel metabolites detailed in this paper can be accurately assessed 
within clinical samples. 
 
  
Page 23 of 27 
 
REFERENCES 
[1] A. Kolb, S. Rieder, D. Born, N. A. Giese, T. Giese, G. Rudofsky, J. Werner, M. W. 
Büchler, H. Friess, I. Esposito, J. Kleeff. Glucagon/insulin ratio as a potential 
biomarker for pancreatic cancer in patients with new-onset diabetes mellitus. Cancer 
Biol. Ther. 2009, 8, 1527. 
[2] F. P. Alford, S. R. Bloom, J. D. Nabarro. Glucagon metabolism in man, studies on the 
metabolic clearance rate and the plasma acute disappearance time of glucagon in 
normal and diabetic subjects. J Clin Endocrinol Metab 1976, 42, 830. 
[3] F. Authier, B. Desbuquois. Glucagon receptors. Cell. Mol. Life Sci. 2008, 65, 1880. 
[4] M. J. Sheetz, H. S. Tager. Characterization of a glucagon receptor-linked protease 
from canine hepatic plasma membranes. Partial purification, kinetic analysis, and 
determination of sites for hormone processing. J. Biol. Chem. 1988, 263, 19210. 
[5] W. A. Hagopian, H. S. Tager. Hepatic glucagon metabolism. Correlation of hormone 
processing by isolated canine hepatocytes with glucagon metabolism in man and in the 
dog. J. Clin. Invest. 1987, 79, 409. 
[6] P. Blache, A. Kervran, D. Le-Nguyen, M. Dufour, A. Cohen-Solal, W. Duckworth, D. 
Bataille. Endopeptidase from rat liver membranes, which generates miniglucagon from 
glucagon. J. Biol. Chem. 1993, 268, 21748. 
[7] G. Fontés, A.-D. Lajoix, F. Bergeron, S. Cadel, A. Prat, T. Foulon, R. Gross, S. Dalle, 
D. Le-Nguyen, F. Tribillac, D. Bataille. Miniglucagon (MG)-generating 
endopeptidase, which processes glucagon into MG, is composed of N-arginine dibasic 
convertase and aminopeptidase B. Endocrinology 2005, 146, 702. 
[8] D. Bataille, G. Fontés, S. Costes, C. Longuet, S. Dalle. The glucagon-miniglucagon 
interplay: a new level in the metabolic regulation. Ann. N. Y. Acad. Sci. 2006, 1070, 
161. 
[9] D. R. Peterson, E. A. Green, S. Oparil, J. T. Hjelle. Transport and hydrolysis of 
glucagon in the proximal nephron. Am. J. Physiol. - Ren. Physiol. 1986, 251, F460. 
[10] J. A. Pospisilik, S. A. Hinke, R. A. Pederson, T. Hoffmann, F. Rosche, D. Schlenzig, 
K. Glund, U. Heiser, C. H. McIntosh, H. Demuth. Metabolism of glucagon by 
dipeptidyl peptidase IV (CD26). Regul. Pept. 2001, 96, 133. 
[11] R. Mentlein. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory 
peptides. Regul. Pept. 1999, 85, 9. 
[12] V. J. Hruby. Structure-conformation-activity studies of glucagon and semi-synthetic 
glucagon analogs. Mol. Cell. Biochem. 1982, 44, 49. 
[13] S. A. Hinke, J. A. Pospisilik, H. U. Demuth, S. Mannhart, K. Kühn-Wache, T. 
Hoffmann, E. Nishimura, R. A. Pederson, C. H. McIntosh. Dipeptidyl peptidase IV 
Page 24 of 27 
 
(DPIV/CD26) degradation of glucagon. Characterization of glucagon degradation 
products and DPIV-resistant analogs. J. Biol. Chem. 2000, 275, 3827. 
[14] M. J. Bak, N. W. Albrechtsen, B. Hartmann, J. Pedersen, M. Christensen, T. Vilsboll, 
F. Knop, C. F. Deacon, L. O. Dragsted, J. J. Holst. No Effect of Aprotinin (Trasylol 
TM
) on Degradation of Exogenous and Endogenous Glucagon in Human , Mouse and 
Rat Plasma. J. Endocrinol. Diabetes 2014, 29, 1. 
[15] J. Mess, R. Lavallee, D. Villeneuve, F. Garofolo, Challenges Associated with the 
Bioanalytical Method Development of the Glucagon by LC-MS in a Regulated 
Environment, in American Association of Pharmaceutical Scientists ConferenceSan 
Diego, CA, May 21–23, 2012. 
[16] BD 
TM
 P800 Blood Collection System Enabling Metabolic Biomarker Preservation 
P800 Preserves Metabolic Peptides. Becton, Dickinson Company, Franklin Lakes, NJ, 
USA 2009. 
[17] J. H. Sloan, R. W. Siegel, Y. T. Ivanova-Cox, D. E. Watson, M. A. Deeg, R. J. 
Konrad. A novel high-sensitivity electrochemiluminescence (ECL) sandwich 
immunoassay for the specific quantitative measurement of plasma glucagon. Clin. 
Biochem. 2012, 45, 1640. 
[18] F. P. Alford, S. R. Bloom, J. D. Nabarro. Glucagon levels in normal and diabetic 
subjects: Use of a specific immunoabsorbent for glucagon radioimmunoassay. 
Diabetologia 1977, 13, 1. 
[19] M. J. Bak, N. W. Albrechtsen, J. Pedersen, B. Hartmann, M. Christensen, T. Vilsbøll, 
F. K. Knop, C. F. Deacon, L. O. Dragsted, J. J. Holst. Specificity and sensitivity of 
commercially available assays for glucagon and oxyntomodulin measurement in 
humans. Eur J Endocrino 2014, 170, 529. 
[20] N. J. Wewer Albrechtsen, B. Hartmann, S. Veedfald, J. a Windeløv, A. Plamboeck, K. 
N. Bojsen-Møller, T. Idorn, B. Feldt-Rasmussen, F. K. Knop, T. Vilsbøll, S. Madsbad, 
C. F. Deacon, J. J. Holst. Hyperglucagonaemia analysed by glucagon sandwich 
ELISA: nonspecific interference or truly elevated levels? Diabetologia 2014, 57, 1919. 
[21] R. Trebbien, L. Klarskov, M. Olesen, J. J. Holst, R. D. Carr, C. F. Deacon. Neutral 
endopeptidase 24 . 11 is important for the degradation of both endogenous and 
exogenous glucagon in anesthetized pigs. Am J Physiol Endocrinol Metab 2004, 3, 
431. 
[22] F. Garofolo, J. N. Mess, L. P. Morin, M. Aiello, X. Misonne, G. Impey, J. Cardenas, J. 
Michon, Glucagon bioanalysis by LC–MS: unprecedented level of sensitivity (10 
pg/ml) for a novel formulation, in 2013 American Association of Pharmaceutical 
Scientists National Biotechnology ConferenceSan Diego, CA, 20-22 May, 2013. 
[23] J. W. Howard, R. G. Kay, T. Tan, J. Minnion, M. Ghatei, S. Bloom, C. S. Creaser. 
Development of a high throughput UHPLC-MS/MS (SRM) method for the 
quantitation of endogenous glucagon from human plasma (accepted, in press). 
Bioanalysis 2014, TBC, TBC. 
Page 25 of 27 
 
[24] D. C. Delinsky, K. T. Hill, C. A. White, M. G. Bartlett. Quantitation of the large 
polypeptide glucagon by protein precipitation and LC/MS. Biomed. Chromatogr. 
2004, 18, 700. 
[25] Y. X. Li, M. Hackman, C. Y. Wang. Quantitation of polypeptides (glucagon and 
salmon calcitonin) in plasma samples by “high resolution” on a triple quadrupole mass 
spectrometer. Bioanalysis 2012, 4, 685. 
[26] V. Lapko, P. Brown, R. Nachi, C. Kafonek, A. Dzerk, B. Retke, C. Ohnmacht, C. 
Sheldon, I. Davis, Exploring quantification of peptides: measurement of glucagon in 
human plasma by LC–MS/MS, in EBF 3rd Annual Open Symposium: From 
Challenges to SolutionsBarcelona, Spain, 1 - 3 December, 2010. 
[27] WMA Declaration of Helsinki - Ethical Principles for Medical Research Involving 
Human Subjects. WMA Gen. Assem. Helsinki, Finland, 1964. 
[28] S. Schilling, T. Hoffmann, S. Manhart, M. Hoffmann, H.-U. Demuth. Glutaminyl 
cyclases unfold glutamyl cyclase activity under mild acid conditions. FEBS Lett. 2004, 
563, 191. 
[29] M. Holčapek, R. Jirásko, M. Lísa. Recent developments in liquid chromatography-
mass spectrometry and related techniques. J. Chromatogr. A 2012, 1259, 3. 
[30] D. S. Rehder, C. R. Borges. Cysteine sulfenic acid as an intermediate in disulfide bond 
formation and non-enzymatic protein folding. Mol. Biomarkers 2011, 49, 7748. 
[31] X. Liang, A. Kaya, Y. Zhang, D. T. Le, D. Hua, V. N. Gladyshev. Characterization of 
methionine oxidation and methionine sulfoxide reduction using methionine-rich 
cysteine-free proteins. BMC Biochem. 2012, 13, 21. 
[32] H. K. Khor, M. E. Jacoby, T. C. Squier, G. C. Chu, D. Chelius. Identification of 
methionine sulfoxide diastereomers in immunoglobulin gamma antibodies using 
methionine sulfoxide reductase enzymes. MAbs 2010, 2, 299. 
[33] F. Authier, B. I. Posner, J. J. Bergeron. Insulin-degrading enzyme. Clin Invest Med 
1996, 19, 149. 
[34] K. Rose, L. A. Savoy, A. V Muir, J. G. Davies, R. E. Offord, G. Turcatti. Insulin 
proteinase liberates from glucagon a fragment known to have enhanced activity against 
Ca2+ + Mg2+-dependent ATPase. Biochem. J. 1988, 256, 847. 
[35] V. S. Sharov, D. A. Ferrington, T. C. Squier, C. Schöneich. Diastereoselective 
reduction of protein-bound methionine sulfoxide by methionine sulfoxide reductase. 
FEBS Lett. 1999, 247.  
 
  
Page 26 of 27 
 
TABLES 
Table 1 Potential metabolites formed by glucagon in human plasma identified   
using LRMS 
Peak Observed 
(m/z)   
Putative 
Charge 
state  
Putative  
mass 
(Da) 
Putative ID Average 
Theoretical 
Mass (Da) 
Mass 
Accuracy 
(ppm) 
1 697.5 5 3482.5 glucagon 1-29 
  
3482.7473 
1
 
  
-82 
1 871.5 4 3482.0 -224 
              
2a 815.1 4 3256.4 glucagon3-29 (?) 
  
3258.53072 
1
 
  
-663 
2a 1086.5 3 3256.5 -630 
              
2b 815.3 4 3257.2 glucagon3-29 (?) 
  
3258.53072 
1
 
  
-418 
2b 1086.4 3 3256.2 -722 
              
2c 815.1 4 3256.4 glucagon 3-29 (?) 
  
3258.53072 
1
 
  
-663 
  1087.4 3 3259.2 198 
              
3 577.3 2 1152.6 glucagon 21-29 1153.30694 
1
 -627 
              
4 641.3 2 1280.6 glucagon20-29 1281.43616 
1
 -665 
              
5 676.8 2 1351.6 glucagon19-29 1352.51406 
1
 -687 
              
6 811.1 4 3240.4  [pGlu]
3
glucagon3–29 
  
3241.5002 
2
 
  
-349 
6 1081.2 3 3240.6 -285 
1 Theoretical average mass value calculated from peptide sequence using 
http://proteomicsresource.washington.edu/cgi-bin/fragment.cgi 
2 Calculated by subtracting NH3 average molecular mass from glucagon3-29 mass. 
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Table 2 Glucagon metabolites in human plasma confirmed using HRMS 
Peak Observed   
(m/z) 
Charge  
state 
Metabolite ID Theoretical   
(m/z) 
Mass Accuracy 
(ppm) 
1 697.12921 5 glucagon1-29 
  
697.13042 
1
 -1.7 
1 871.15967 4 871.16120 
1
 -1.8 
      
2a 814.87933 4 oxidised [pGlu]
3
glucagon3–29 
  
814.88056 
2
 -1.5 
2a 1086.17004 3 1086.17165 
2
 -1.5 
     
 
  
2b 814.87933 4 oxidised [pGlu]
3
glucagon3–29 
  
814.88056 
2
 -1.5 
2b 1086.17029 3 1086.17165 
2
 -1.3 
   
  
  
2c 815.13751 4 glucagon 3-29  
  
815.13847 
1
 -1.2 
2c 1086.51331 3 1086.51553 
1
 -2.0 
     
 
  
3 577.26898 2 glucagon 21-29   
  
577.27097 
1
 -3.4 
3 1153.53027 1 1153.53466 
1
 -3.8 
   
  
  
4 641.29828 2 glucagon 20-29  
  
641.30026 
1
  -3.1 
4 1281.58899 1 1281.59324 
1
 -3.3 
   
  
  
5 676.81628 2 glucagon19-29 
  
676.81881 
1
 -3.7 
5 1352.62651 1 1352.63035 
1
 -2.8 
      
6 810.87982 4  [pGlu]
3
glucagon3–29 
  
810.88183 
2
 -2.5 
6 1080.8374 3 1080.84001 
2
 -2.4 
 
1 Theoretical monoisopic value calculated from peptide sequence using 
http://proteomicsresource.washington.edu/cgi-bin/fragment.cgi 
2 Values calculating from other masses in table by the masses of modifications in 
http://www.weddslist.com/ms/tables.html 
 
Table 3 Glucagon degradation after 1 month and 5 months in a freezer 
Sample  
(stabiliser/ storage conditions) 
% stability 
1 
Month 
5 
Months 
Aprotinin stabilised  (-20C) 103.4 86.6 
Unstabilised  (-20C) 88.1 85.5 
Aprotinin stabilised  (-80C) 98.8 91.6 
Unstabilised  (-80C) 89.6 91.9 
 
